Kedaara takes majority stake in Tynor in $200m orthopaedic supports deal
Kedaara Capital has acquired a 51% stake in Mohali-based Tynor Orthotics for about $200 million, facilitating Lighthouse Funds’ exit. The maker of orthopaedic support wear plans to expand its India and international footprint, strengthen manufacturing and build a wider orthopaedic and wellness platform.
What happened
Tynor Orthotics · Kedaara Capital acquired a majority stake in Mohali-based orthopaedic supports maker Tynor for about $200 million, enabling Lighthouse Funds’
Key facts
- $200 million (Rs 1,907 crore) transaction value
- 51% stake acquired
- Founded in 1993
- More than 300,000 retail outlets
- 8,000 hospitals
- Operations in 60 nations
- 3 manufacturing units in India
- Rs 143 crore invested by Lighthouse Funds and Thuasne Participations in 2018
Why this matters
The deal validates orthopaedic supports as an attractive platform category, with Tynor now positioned to pursue adjacent wellness acquisitions and partnerships after Lighthouse Funds’ exit.
What to watch
- New factory, capacity-expansion or automation announcements.
- Growth in export revenue, new country registrations and international distributor deals.
- Hospital-chain, pharmacy-chain, e-commerce or insurer partnerships.
- Acquisitions in rehabilitation, mobility, home healthcare or wellness categories.
- Evidence of ASP increases, product premiumization and margin improvement.
- Changes in orthopaedic-support reimbursement, medical-device regulation or import/export requirements.
- Competitive pricing moves by domestic manufacturers and global medical-support brands.
- Increase manufacturing capacity, automation and quality-control infrastructure in India.
- Expand sales coverage in hospitals, orthopaedic clinics, physiotherapy centers and organized pharmacy chains.
- Launch adjacent products in rehabilitation, sports recovery, mobility and preventive wellness.
- Pursue export-market registrations and distributor partnerships, especially in Gulf and other high-demand markets.
- Evaluate tuck-in acquisitions that add clinical credibility, new product categories or international distribution.
- Professionalize governance, financial reporting and supply-chain systems ahead of a potential strategic sale or IPO.